October SPAC Merger Calendar: A Look At Upcoming Votes, Stocks To Watch
The month of October marks a slowdown in SPAC merger deal votes, but the calendar does include several multibillion-dollar deals.
SPAC merger votes can act as a catalyst, as it completes the last step in the merger process and also changes the company over to a new name and ticker that can help build recognition.
Northland Capital Markets Initiates Coverage On Big Cypress Acquisition with Outperform Rating, Announces Price Target of $18
Northland Capital Markets analyst Tim Chiang initiates coverage on Big Cypress Acquisition (NASDAQ:BCYP) with a Outperform rating and announces Price Target of $18.
Big Cypress Acquisition Merger Partner SAB Biotherapeutics Announces First Patient Dosed In Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 For Treatment Of COVID-19
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human
Ladenburg Thalmann Initiates Coverage On Big Cypress Acquisition with Buy Rating, Announces Price Target of $16.5
Ladenburg Thalmann analyst Jeffrey Cohen initiates coverage on Big Cypress Acquisition (NASDAQ:BCYP) with a Buy rating and announces Price Target of $16.5.
SAB Biotherapeutics Awarded Additional $60.5M From BARDA And U.S. Department Of Defense For Rapid Response Capability And Advancing SAB-185 For Treatment Of COVID-19
$200 million total awarded to date for DiversitAb™ Rapid Response Antibody Program including Stage 4 COVID-19 Pandemic Response
Expanded contract scope includes commercial manufacturing and clinical
Big Cypress Acquisition Corp. SPAC Merger Partner, SAB Biotherapeutics, Highlights Publication Of Preclinical Data Showing SAB-185 Effectively Neutralizes SARS-CoV-2 Variants
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibody therapeutics, today announced
Big Cypress Acquisition Corp. SPAC Merger Partner SAB Biotherapeutics Highlights Publication Of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants
Findings Published in Human Vaccines & Immunotherapeutics Show SAB-185 Neutralizes Virus Strains Containing Substitutions Present in Variants of Concern
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical
SAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of Influenza
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies, today announced that the